Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Bicara Therapeutics Inc (BCAX)

October 14, 2025 6:39 AM EDT Send to a Friend
H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $40.00 price target on Bicara Therapeutics Inc (NASDAQ: BCAX).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login